ERBB2 and breast cancer: Among patients with HER2-low-expression BC, 11 patients (26.8%) received monotherapy, while 30 patients (73.2%) received combination therapy, including 8 patients (19.5%) with chemotherapy, 14 patients (34.1%) with targeted therapy, and 8 patients (19.5%) with other combination therapies, including 5 patients receiving both chemotherapy and targeted therapy, 2 patients receiving endocrine therapy, and 1 patient receiving immunotherapy.